Jump to content
Main menu
Main menu
move to sidebar
hide
Navigation
Main page
Recent changes
Random page
freem
Search
Search
Appearance
Create account
Log in
Personal tools
Create account
Log in
Pages for logged out editors
learn more
Contributions
Talk
Editing
Openai/692df380-fd64-8008-b788-94e93ef3ff89
(section)
Add languages
Page
Discussion
English
Read
Edit
Edit source
View history
Tools
Tools
move to sidebar
hide
Actions
Read
Edit
Edit source
View history
General
What links here
Related changes
Special pages
Page information
Appearance
move to sidebar
hide
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
==== 5. Safety, trade-offs, and potential risks ==== Preclinical data highlight that KMO inhibition is not an unambiguous win: # Excess KYNA and cognition/mood - Mice with KMO deficiency (high KYNA) display depression-like behavior, attributed to enhanced antagonism of α7-nicotinic receptors by KYNA. ScienceDirect<ref>{{cite web|title=ScienceDirect|url=https://www.sciencedirect.com/science/article/abs/pii/S0166432821000796|publisher=sciencedirect.com|access-date=2025-12-28}}</ref> - Elevated KYNA and KMO knockout models impair spatial working memory and LTP; KAT II inhibition (reducing KYNA) restores glutamatergic signaling and LTP. PMC<ref>{{cite web|title=PMC|url=https://pmc.ncbi.nlm.nih.gov/articles/PMC8411644/|publisher=pmc.ncbi.nlm.nih.gov|access-date=2025-12-28}}</ref> - Human data associate high brain KYNA with cognitive impairment in schizophrenia and possibly other conditions. Wiley Online Library<ref>{{cite web|title=Wiley Online Library|url=https://onlinelibrary.wiley.com/doi/10.1111/cns.13768|publisher=Wiley Online Library|access-date=2025-12-28}}</ref> Implication: Over-inhibiting KMO (and thus over-producing KYNA) may trade neuroprotection for impaired cognition and mood. # NAD⁺ metabolism - QUIN is a precursor for de novo NAD⁺ synthesis. Chronic, strong KMO inhibition might slightly alter NAD⁺ homeostasis, especially in tissues reliant on de novo synthesis. Reviews acknowledge this but the net impact in vivo is unresolved. PMC<ref>{{cite web|title=PMC|url=https://pmc.ncbi.nlm.nih.gov/articles/PMC8747024/|publisher=pmc.ncbi.nlm.nih.gov|access-date=2025-12-28}}</ref> # Unknowns in long-term systemic inhibition - No long-term human data on infection risk, tumor surveillance, metabolic side-effects, or subtle CNS changes. - KMO is expressed in immune cells; chronic inhibition could theoretically modulate host defense, but data are sparse. PMC<ref>{{cite web|title=PMC|url=https://pmc.ncbi.nlm.nih.gov/articles/PMC8747024/|publisher=pmc.ncbi.nlm.nih.gov|access-date=2025-12-28}}</ref>
Summary:
Please note that all contributions to freem are considered to be released under the Creative Commons Attribution-ShareAlike 4.0 (see
Freem:Copyrights
for details). If you do not want your writing to be edited mercilessly and redistributed at will, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource.
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)